Rapport Therapeutics, Inc. RAPP Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78.06M+35.5% | $52.65M-7.3% | $251.36M+539% | $55.07M-50.0% | $57.6M-22.4% | ||
| $398.73M+75.1% | $437.89M+76.2% | $261.67M-7.0% | $205.38M-9.1% | $227.78M— | ||
| $58K— | $0— | —— | —— | $0— | ||
| $484.7M+66.6% | $498.56M+60.9% | $520.66M+59.7% | $270.24M-20.7% | $290.97M— | ||
| $2.52M-26.0% | $2.98M-15.7% | $3.12M-8.6% | $3.17M-8.7% | $3.4M— | ||
| $497.6M+64.7% | $512.43M+62.7% | $535.32M+61.7% | $285.5M-17.5% | $302.05M— | ||
| $6.56M+207% | $4.19M+114% | $3.24M+145% | $3.18M+69.4% | $2.14M+289% | ||
| $17.9M+90.7% | $19.05M+117% | $14.32M+102% | $11.88M+46.7% | $9.38M— | ||
| $26.09M+60.8% | $27.78M+192% | $23.71M+195% | $21.98M+139% | $16.22M— | ||
| $48K+29.7% | $48K+29.7% | $48K+33.3% | $37K+2.8% | $37K— | ||
| -$255.09M-72.6% | -$235.23M-90.1% | -$201.47M-94.2% | -$174.54M-102% | -$147.81M— | ||
| $471.51M+65.0% | $484.65M+58.7% | $511.62M+58.3% | $263.51M-21.8% | $285.84M+821% | ||
| $497.6M+64.7% | $512.43M+62.7% | $535.32M+61.7% | $285.5M-17.5% | $302.05M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rapport Therapeutics, Inc.'s total assets?
- Rapport Therapeutics, Inc. (RAPP) holds $497.6M in total assets, up 64.7% year over year.
- How much debt does Rapport Therapeutics, Inc. have?
- Rapport Therapeutics, Inc. carries $10.8M in total debt against $471.5M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Rapport Therapeutics, Inc. have?
- Rapport Therapeutics, Inc. holds $78.1M in cash and equivalents.
- Can Rapport Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 27.08 — current assets exceed current liabilities.
- Where does Rapport Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.